Paper Details

  1. Home
  2. Paper Details

Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.

Author: AlexanianRaymond, AlsinaMelissa, AndersonKenneth C, BarlogieBart, BerensonJames R, EsseltineDixie-Lee, IrwinDavid, JagannathSundar, LimentaniSteven A, NiesvizkyRuben, RichardsonPaul G, SiegelDavid S

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study presents updated survival data from the CREST trial, which investigated the effectiveness of bortezomib in treating relapsed or refractory multiple myeloma. The data suggests that a starting dose of 1.3 mg/m(2) of bortezomib is preferable, while a dose of 1.0 mg/m(2) still offers significant survival benefit if a dose reduction is necessary.
Paper Details　
Original Abstract of the Article :
The Clinical Response and Efficacy Study of Bortezomib in the Treatment of Relapsing Multiple Myeloma (CREST) demonstrated substantial activity with two dose levels of bortezomib (1.0 and 1.3 mg/m(2)), alone or with dexamethasone, in relapsed or refractory multiple myeloma. We present updated surviv...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1365-2141.2008.07359.x

データ提供：米国国立医学図書館（NLM）

Updated Survival Analyses After Prolonged Follow-Up of the CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma

This research delves into the realm of cancer treatment, specifically focusing on the effectiveness of bortezomib in treating relapsed or refractory multiple myeloma. The study utilizes a [research methodology] approach to analyze survival data from the CREST study after a prolonged follow-up period. The authors report the [key findings], highlighting a notable survival benefit associated with a higher starting dose of bortezomib, suggesting that this dose may be preferred for patients with relapsed or refractory multiple myeloma.

Bortezomib: A Potential Treatment Option for Relapsed or Refractory Multiple Myeloma

The study provides valuable insights into the effectiveness of bortezomib in treating patients with relapsed or refractory multiple myeloma. The [key findings] indicate that bortezomib, at a higher starting dose, can significantly improve survival outcomes for patients with this challenging condition. This is a promising development in the search for more effective treatments for multiple myeloma.

The Importance of Research in Cancer Treatment

This study underscores the importance of continuous research and development in cancer treatment. By analyzing long-term survival data, researchers can gain valuable insights into the effectiveness of existing treatments and identify potential areas for improvement. This study serves as a reminder that the search for better cancer treatments is an ongoing journey, driven by the commitment of researchers to improving patient outcomes and quality of life.

Dr.Camel's Conclusion

This research provides a deeper understanding of the effectiveness of bortezomib in treating multiple myeloma, a challenging condition that affects many individuals. The study highlights the importance of ongoing research and analysis of long-term data in cancer treatment, paving the way for more effective treatments and improved patient outcomes. As a researcher, I am always inspired by the dedication of scientists in the field of cancer research, working tirelessly to find new ways to combat this devastating disease and provide hope for those affected.
Date :
  1. Date Completed 2009-01-07
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

18783399

DOI: Digital Object Identifier

10.1111/j.1365-2141.2008.07359.x

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.